DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium | Zendy

AI Assistant Blog Pricing

DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.